Related Experiment Video
Updated: Jan 13, 2026
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Albumin Nanoparticles in Cancer Therapeutics: Clinical Status, Challenges, and Future Directions
Hachemi Kadri1, Mesk Alshatfa1, Feras Z Alsalloum1
1Drug Discovery, Delivery and Patient Care (DDDPC) Theme, School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston Upon Thames KT1 2EE, UK.
Abstract:
Cancer, a global health burden, is characterized by uncontrolled cell growth and metastasis, often resulting in debilitating treatments and mortality. While conventional therapeutic strategies have improved survival rates, they are limited by challenges such as off-target toxicity and drug resistance. With their design to enable targeted drug delivery, nanoparticles have presented a promising avenue to overcome these limitations. Protein-based nanoparticles, particularly those based on albumin, are notable for their biocompatibility, stability, and ease of modification. The approval of Abraxane, an albumin-based nanoparticle formulation of paclitaxel, for metastatic breast cancer marked a significant milestone. However, further approvals have been slow to materialize until the recent approval of Fyarro® in 2021. This focused review highlights the potential of albumin-based nanoparticles, emphasizing their advantages, current state, and progress in clinical use as anticancer therapeutics. We also discuss challenges impeding new approvals and future directions for unlocking the full potential of this technology.
Insights
Albumin-based nanoparticles offer targeted cancer drug delivery, overcoming limitations of traditional therapies. Recent approvals highlight their potential, but challenges remain for wider clinical use.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cancer presents a significant global health challenge, with conventional treatments facing limitations like toxicity and drug resistance.
- Nanoparticles, particularly protein-based ones like albumin nanoparticles, show promise for targeted drug delivery in cancer therapy.
- Albumin nanoparticles are favored for their biocompatibility, stability, and ease of modification.
Purpose of the Study:
- To review the potential of albumin-based nanoparticles as anticancer therapeutics.
- To emphasize the advantages, current clinical status, and progress of albumin-based nanoparticles.
- To discuss challenges and future directions for albumin-based nanoparticle drug delivery systems.
Main Methods:
- Literature review focusing on albumin-based nanoparticles in cancer therapy.
- Analysis of clinical approvals and progress of albumin-based nanoparticle formulations.
- Discussion of challenges and future research avenues.
Main Results:
- Abraxane (albumin-bound paclitaxel) approval was a milestone, but further approvals were slow until Fyarro® in 2021.
- Albumin nanoparticles demonstrate significant potential for targeted anticancer drug delivery.
- Several challenges impede the broader clinical approval and application of these nanotherapeutics.
Conclusions:
- Albumin-based nanoparticles represent a promising platform for developing effective and targeted anticancer therapies.
- Overcoming current challenges is crucial for unlocking the full therapeutic potential of albumin nanoparticles.
- Continued research and development are essential for advancing albumin-based nanomedicine in oncology.
